Sputum Changes Associated with the Use of Ipratropium Bromide
| Autor: | Kashinath D. Patil, Irving Kass, Mo Ghafouri |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Intoxicative inhalant Neutrophils Ipratropium bromide Critical Care and Intensive Care Medicine Placebo Double-Blind Method Humans Medicine Atropine Derivatives Bronchitis Adverse effect Aged business.industry Ipratropium Sputum Middle Aged medicine.disease Respiratory Function Tests respiratory tract diseases Eosinophils Anesthesia Breathing Drug Evaluation Female medicine.symptom Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Chest. 86:387-393 |
| ISSN: | 0012-3692 |
| DOI: | 10.1378/chest.86.3.387 |
| Popis: | Long-term effects of ipratropium bromide (IB) were evaluated using a double-blind cross-over design in 23 adult chronic bronchitic participants. Two 20-micrograms doses of either IB or placebo were administered as an inhalant four times a day for a period of seven weeks. Sputum volume expectorated during a 24-hour period decreased significantly (p less than 0.05) over the entire length of the study, but sputum viscosity or its dry weight were not affected. Although total number of inflammatory cells in sputum was decreased by the use of IB (p less than 0.05), macrophages increased slightly. Subjects coughed less while receiving IB, and their cough was less severe (p less than 0.05). Ipratropium bromide caused a significant improvement (p less than 0.05) in the mechanics of breathing primarily in the subjects between 46 to 55 years of age. No major adverse reaction to IB was recorded. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|